TRIVECTIN A

TRIVECTIN A is a dual-antiparasitic combination targeting intestinal and tissue helminths through two complementary mechanisms that together cover a broader spectrum of parasitic infections than either agent alone.

Albendazole (400mg) is a broad-spectrum benzimidazole antiparasitic. It acts by selectively binding to the beta-tubulin subunit of parasitic microtubules, inhibiting tubulin polymerisation. This prevents the formation of the cytoskeletal microtubule apparatus that parasites depend on for cell division, intracellular transport, and glucose uptake. Without functional microtubules, the parasite cannot absorb glucose, undergo cell division, or maintain structural integrity — leading to energy depletion, immobilisation, and death. Albendazole's metabolite, albendazole sulphoxide, is the pharmacologically active form and achieves excellent penetration into systemic tissues, making it effective against both luminal and tissue-invasive parasites including Ascaris, Hookworm, Strongyloides, Trichuris, Enterobius, Giardia, Neurocysticercosis, Hydatid disease, and Lymphatic filariasis.

Ivermectin (6mg) is a macrocyclic lactone antiparasitic with a distinct mechanism — it activates glutamate-gated chloride ion channels unique to invertebrates (absent in mammals), causing hyperpolarisation of nerve and muscle cell membranes. This results in neuromuscular paralysis and death of the parasite. Ivermectin is particularly effective against microfilariae (larval stages of filariid parasites), ectoparasites (scabies, head lice), and intestinal strongyloidiasis. Its distribution into skin tissue is exceptional, making it the agent of choice for ivermectin-responsive dermatological parasitic conditions.

The combination of albendazole and ivermectin achieves synergistic antiparasitic activity — albendazole covering the macrofilarial and helminthic spectrum while ivermectin kills microfilariae and ectoparasites — providing comprehensive cover for the mixed parasitic infections common in tropical settings.

TRIVECTIN A is indicated for a broad range of parasitic infections in adults and children above 15 kg, particularly in tropical and endemic settings where mixed infections are prevalent.

Lymphatic Filariasis (LF): The most significant indication globally. WHO-recommended mass drug administration (MDA) for LF elimination programmes uses the albendazole + ivermectin combination (or albendazole + diethylcarbamazine in non-onchocerciasis co-endemic areas). The combination clears microfilaraemia and reduces adult worm transmission more effectively than either drug alone.

Soil-Transmitted Helminths: Ascariasis, Hookworm (Ancylostoma duodenale and Necator americanus), Trichuriasis, Enterobiasis, and Strongyloidiasis — albendazole provides reliable coverage for all of these common intestinal worms.

Scabies: Ivermectin is the systemic agent of choice for complicated or crusted scabies, and for community outbreak management where topical therapy is impractical. The combination with albendazole covers concurrent intestinal worm infection common in scabies-endemic communities.

River Blindness (Onchocerciasis): Ivermectin is the primary agent for onchocerciasis control; albendazole provides additive helminthic benefit in co-endemic areas.

Strongyloidiasis: Ivermectin is the preferred agent for Strongyloides stercoralis — the combination ensures complete coverage of concurrent helminthic infection.

Ectoparasitic Infections: Pediculosis capitis (head lice) and cutaneous larva migrans where systemic therapy is preferred.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.